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The participation of glucose and two intermediates of glucose metabolism: glucose-6-phosphate (G6P) and glyceraldehyde-3-phosphate
(Gald3P) to the formation of early glycation products was comparatively evaluated in the endothelial plasma membrane of streptozotocin-induced
diabetic rats. Antibodies risen to a carrier protein reductively glycated by each of the sugars mentioned above were used to probe by
immunoblotting the proteins of the lung microvascular endothelium plasmalemma purified from normal and diabetic rats. The amount of glycated
endothelial plasma membrane proteins was below the limit of detection in normoglycemic animals but increased dramatically in diabetic animals
for glucose and G6P. In contrast, no signal was found in diabetic rats for Gald3P, indicating that either the contribution of this phosphotriose to the
glycation of intracellular proteins is negligible in vivo, or the Schiff base generated by this sugar transforms very rapidly into products of advanced
glycation. Globally, the endothelial plasma membrane proteins bound on average 300 times more glucose than G6P proving that, in spite of its low
in vitro potency as glycating agent, glucose represents the main contributor to the intracellular formation of early glycation products. The most
abundant glycated proteins of the lung endothelial plasma membrane were separated by two dimensional electrophoresis and identified by mass
spectrometry.
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Reducing sugars such as glucose are able to bind covalently
to the free amino residues of proteins—a process called
glycation. Protein glycation is a reaction proceeding in steps,
in the absence of any enzyme intervention. The first product is
a labile Schiff base that is rearranged over a period of days into
the more stable, Amadori products. These sugar-peptide
adducts are known as ‘‘early glycation products’’. Through
oxidation and fragmentation, the Amadori products evolve
gradually towards a heterogeneous and still incompletely
characterized population of macromolecules, labeled ‘‘ad-
vanced glycation end products’’ or AGEs [1]. These altered
proteins carry highly reactive free radicals and may contain
extensive intra and intermolecular cross-links. As a non-
enzymatic process, the extent of the protein glycation depends0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: ghitescd@patho.umontreal.ca (L. Ghitescu).essentially on the concentration of sugar; it is therefore minimal
in physiological, normoglycemic conditions, but increases
dramatically in both types of diabetes, where hyperglycemia
greatly accelerates the reaction [2].
Both early and advanced glycation products are seen as
important players in the mechanism of diabetic vascular
complications. Numerous studies have been focused on the
detrimental role of glycation on the physiology of endothelial
cells; either glycated extracellular matrix components [3] or
AGE-modified circulating proteins [4] have been implicated.
Comparatively, very little is known about the glycation of
intracellular endothelial proteins, although the general view is
that this process might alter their functions. Identification of the
intracellular glycated proteins of endothelium appears therefore
as an important step for understanding the complexity of the
diabetes-induced endothelial dysfunction.
Studies performed in vitro have shown that glucose is a
relatively weak glycation agent while other reducing sugars,
such as the intermediates of the glucose metabolism: glucose-
6-phosphate (G6P) and glyceraldehyde-3-phosphate (Gald3P),a 1762 (2006) 94 – 102
http://www
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these sugars would dominate the process of intracellular
proteins glycation [5–8].
The goal of the present investigation was to evaluate
comparatively the contribution of glucose, G6P and Gald3P
to the glycation of the endothelial plasma membrane proteins
and to identify the targeted proteins. We choose to study this
cellular compartment because it plays a crucial role in the
majority of the endothelial/vascular functions: control of the
vascular tone and of the coagulation, diapedesis of leucocytes,
selection and transmural transport of plasma macromolecules.
This study was performed on lung microvascular endothe-
lium. The richness of the pulmonary vascular bed yields
enough endothelial plasma membrane to allow the handling of
each animal in experience as an independent sample. The data
in the literature on endothelial glucose transporters indicate that
in diabetes all types of endothelial cells are loaded with glucose
[9–11]. Therefore, it was plausible to assume that a nonenzy-
matic process such as protein glycation progresses similarly in
all endothelia; in this perspective, the lung endothelium
represents a convenient model of investigating this process.
2. Materials and methods
2.1. Preparation of antibodies recognizing early glycation products of
proteins
Keyhole limpet hemocyanin (KLH) was glycated in sterile conditions with
glucose, G6P or Gald3P (Sigma Aldrich, St. Louis MO). Sodium cyanobor-
ohydride (150 mM) present throughout the incubation transformed all the labile
early glycation products into stable epitopes (mostly glucitollysine, glucitol-6-
phosphate lysine and glyceraldehyde-3-phosphate lysine) that allow the
subsequent immunodetection of the proteins glycated by each of the three
sugars [12]. The glycated KLH was used as an immunogen to generate rabbit
polyclonal antibodies against the adducts of lysine with each of the three sugars
listed above. The anti KLH-glucose, KLH-G6P and KLH-Gald3P immunoglo-
bulins were purified on Protein A-Sepharose (Amersham-Pharmacia Biotech-
nol., Piscataway, NJ) and cleared of the anti-carrier (KLH) antibodies on an
immobilized KLH-Sepharose column (Sigma Aldrich).
The ability of these antibodies to recognize selectively the corresponding
sugar haptens on proteins different from the immunogen was tested on glycated
bovine serum albumin (BSA). BSA fraction V (Sigma Aldrich) was glycated in
reductive conditions with glucose, fructose, G6P and Gald3P, respectively.
BSA reductively modified by carboxymethyllysine (CML) and carboxyethyl-
lysine (CEL), two AGEs-characteristic epitopes, was prepared according to
Nagai et al. [13]. The unbound sugar was removed by extensive dialysis against
PBS, the concentration of glycated BSA was evaluated spectrophotometrically
(A280 nm=0,7 for 1 mg/ml BSA) and the extent of glycation was determined in
each sample by the fluorescamine method [14]. The number of sugar residues
introduced by glycation per BSA molecule was calculated by taking into
account that each native BSA molecule has 59 available lysine ( NH2 groups.
An average sugar/BSA molar ratio of 57, 14.7, 46.6 and 8.3 was found for
BSA-glucose, BSA-fructose, BSA-G6P and BSA-Gald3P respectively. The
degree of substitution of amino residues for BSA-CML and BSA-CEL was of
84% and 98%, respectively.
To assess the specificity and the sensitivity of the antibodies to particular
sugar—lysine adducts, native, unglycated BSA was mixed with each of the
glycated BSA variants in proportions keeping the total protein concentration
constant (1 mg/ml) but serially decreasing the amount of bound sugar from 128
to 1 nmol/ml. Parallel rows of dots were made by absorbing 1 Al of the above
serial samples on nitrocellulose membranes that were subsequently blocked for
1 h in 1% non-fat dry milk and probed separately with each of the antibodies
described. The primary antibody was followed by anti-rabbit Ig-HRP (JacksonImmunoResearch; West Grove, PA) and the signal was detected by enhanced
chemiluminescence (ECL kit, Roche Diagnostics BM).
2.2. Animal model
Six male Sprague–Dawley rats, 125 g body weight (Charles River; St-
Laurent, QC) were rendered diabetic by a single i.p. injection of streptozotocin
(STZ) (70 mg/kg of body weight) and maintained for a period of 2 months.
Their glycemia was tested with a GlycoTest II kit (Roche Diagnostics, Laval,
QC). An equal number of age-matched rats were used as normoglycemic
controls. All animals were permitted free access to a standard diet and water.
The following parameters were measured at the time of sacrifice for validating
the diabetic state of the animals in the experimental lot : body weight (289T40
g for diabetic and 392T41 g for control rats), glycemia (>29 mM vs. 7.1T0.8
mM), and the percentage of glycated plasma proteins measured by the
aminophenylboronate affinity chromatography [15] (2.6%T0.3 in the diabetic
vs. 1.1%T0.1 in the normal lot). The experiments were approved by the
institutional Committee of Deontology for the Experimentation on Animals.
2.3. Immunochemical detection of the glycated proteins of the
endothelial plasma membrane
The apical aspect (blood front) of the endothelial plasma membrane was
isolated from the rat lung microvasculature by the cationic colloidal silica
method [16,17]. Protein concentration was measured in quadruplicates by the
Amidoblack method [18] in samples previously solubilized in 1% SDS.
The glycation of the endothelial membrane (operationally labeled P2
fraction) proteins by glucose, G6P and Gald3P was first explored using one-
dimensional electrophoresis and immunoblotting with the corresponding
antibodies. For each animal, normal and diabetic, 30 Ag P2 were resolved by
SDS-PAGE. The proteins were electrotransferred to nitrocellulose and the
membranes were incubated in 50 mM sodium borohydride (Sigma Aldrich) for
15 min to irreversibly transform the early glycation products into the stable
forms: glucitollysine, G6P-lysine and Gald3P-lysine, detectable by our
antibodies. The membranes were blocked in 1% defatted milk and probed
with the polyclonal anti-glucitollysine (1:2000 dilution), anti-G6P-lysine
(1:200) and anti-Gald3P-lysine (1:500) antibodies overnight, followed by 1-
h incubation with a 1:10.000 dilution of anti-rabbit Ig-HRP and development
by ECL.
To comparatively evaluate the extent of glycation by each of the sugars
taken into consideration, a semi-quantitative immunochemical assay was
employed. As the previously described immunoblotting experiment did not
detect any early glycation products made by Gald3P, the quantification assay
was performed for glucose and G6P only. Five to twenty micrograms of total
lung endothelial membrane proteins purified from diabetic rats (P2 fraction),
solubilized in 1% SDS, were absorbed on nitrocellulose as dots along with
standards made of serial mixtures of BSA and reductively glycated BSA, as
described in the first paragraph. The glucitollysine and G6P-lysine epitopes
were revealed by immunoblotting with the corresponding antibodies and the
intensity of the signal was measured on film by densitometry for each spot
using the Scion Image program (Scion Corp, Frederick, MA). A standard curve
was created for each hapten, and the extent of glycation of the P2 proteins was
evaluated by interpolation.
2.4. Two dimension electrophoretic separation and mass spectrometry
identification of the glycated proteins
Eight hundred micrograms of lung endothelial plasma membrane proteins
from a control, normoglycemic animal were solubilized for isoelectric
focussing in 20 mM Tris buffer containing 8 M urea, 2 M thiourea, 4%
CHAPS, 40 mM dithioerythriol and 2% ampholytes mixture for immobilized
4–7 pH gradient [19]. After removal of the silica nanoparticles by
microcentrifugation, the proteins were loaded onto an Immobiline Dry strip
pH 4–7, 18 cm (Amersham Biosciences, Piscataway, NJ). The first dimension
run was followed by SDS-PAGE in a 10% acrylamide, 20-cm gel in the second
dimension. The gel was stained by Sypro Ruby (Molecular Probes, Eugene,
OR) and scanned (BioRad Molecular Imager ProPlusFX) to obtain the global
Fig. 1. The sensitivity and specificity of the antibodies against glucitol-lysine
(A), glucitol-6-phosphate lysine (B), and glyceraldehyde-3-phosphate lysine
(C) evaluated by immunoblotting of serum albumin glycated by various sugars
Each dot contains 15 pmol (1Ag) BSA and varying amounts (1–128 pmol) o
bound sugars.
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this time from a diabetic rat, were resolved by 2D electrophoresis in identical
conditions, electrotransferred to nitrocellulose, reduced by NaBH4, and stained
with Sypro Ruby Protein Blot Stain (BioRad Laboratories Canada, Mis-
sissauga, ON) before being separately submitted to immunoblotting with anti-
glucitollysine and anti-G6P-lysine antibodies, as described above. The
comparisons between the three patterns (immunoblot, Sypro Ruby on
nitrocellulose and Sypro Ruby in gel) allowed for an unambiguous
identification of the position, in the gel, of each glycated polypeptide, within
the spectrum of all endothelial membrane proteins. This operation was
facilitated by the lack of qualitative differences in the 2D electrophoretic
pattern of endothelial membranes of normo- and hyperglycaemic rats. To check
for reproducibility, this experiment was repeated three times using different,
independently purified endothelial plasma membrane from normal and diabetic
animals.
The major spots corresponding to the glycated proteins were manually cut
out of the Sypro Ruby stained gel using a biopsy needle and stored in 1% acetic
acid. The proteins contained were digested with trypsin (6 ng/Al) for 5 h on a
MassPrep robotic workstation (Micromass). Peptides were extracted in a final
volume of 45 Al of 0.5% formic acid (v/v) and 9% acetonitrile (v/v).
Analysis of extracted tryptic peptides by LC-QTOF mass spectrometry
(MS) was performed by applying the samples to a reverse phase column (10 cm
by 75 Am PicoFrit column filled with BioBasic C18). The column bound
material was eluted in-line at 200 nl/min, over a 30-min interval, with a linear
gradient of 10–95% acetonitrile containing 0.1% formic acid throughout. A
2000-V charge was applied to the PicoFrit column such that the eluted peptides
were electrosprayed into a capillary liquid chromatography quadrupole time-of-
flight MS (LC-Micro Q-TOF) (Waters). Double or triple charged detected ions
were selected for passage into a collision cell where fragmentation was induced
by collision with argon gas. Fragmentation data were collected in 1 s. scans for
up to 5 s. The MS/MS data were peaklisted with Masslynx (MicroMass) and
submitted to Mascot (MatrixScience) software for database search analysis
against the NCBI non-redundant database. The MALDI MS survey scans were
used to generate peak lists for peptide map searches using the peptide mass
fingerprint search option in Mascot.
3. Results
The specificity and sensitivity of the antibodies obtained
from rabbits immunized with glycated KLH was evaluated by a
dot blot assay, against BSA reductively glycated with glucose,
fructose, G6P, Gald3P, CML and CEL (Fig. 1). The test
demonstrated that the antibodies showed a high degree of
specificity towards their corresponding epitopes. No reaction
existed between the antibodies and native, un-glycated BSA.
Also, there were no reactions between our anti-glucitollysine
antibody with G6P-BSA, the anti-G6P-lysine antibody with
glucose-BSA, and our anti Gald3P-lysine antibody with BSA
glycated by either glucose or G6P. Both anti-glucitollysine and
anti-G6P-lysine show a slight cross-reaction with Gald3P-BSA
but, as it will be seen further on, this does not alter the validity
of the results and conclusions. No reaction was recorded
between any of the three antibodies and BSA glycated with
fructose or carrying AGE epitopes (CML and CEL). Identical
results were obtained when the test was repeated with glycated
hemoglobin (not shown), stressing the fact that our antibodies
recognized the early-glycation related epitopes irrespective of
their carrier protein.
It has been previously documented by others [16] and by
us [17] that the cationic colloidal silica method yields very
highly purified preparations of lung endothelial plasma
membranes (luminal or blood front). The proteins of these
membranes, separately purified from each animal, were.
fresolved by SDS-PAGE and comparatively probed by
Western blotting with each of the previously described
antibodies. Within each of the two experimental groups
(diabetic and control), the results were the same, so Fig. 2
illustrates a representative pair from these lots only. The
silver-stained SDS-PAGE gel shows a virtually identical
profile for endothelial plasma membrane proteins from normal
and hyperglycemic rats (Fig. 2A). However, significant
differences between these two categories are detected at the
level of protein glycation. Effectively, no signal for glycation
was detected in the membranes obtained from normal rats and
incubated with anti-glucitollysine antibodies (Fig. 2B), and
only two bands of relatively low intensity were revealed by
both the anti-G6P-lysine and anti-Gald3P-lysine (Fig. 2C and
D). In contrast, a high level of glycation was exposed by the
anti-glucitollysine and anti-G6P-lysine antibodies in endothe-
lial membranes purified from hyperglycemic animals. The
pattern of bands produced by these two antibodies in samples
from diabetic rats is practically the same, with a significantly
more intense reaction for anti-glucitollysine (Fig. 2B and C).
Surprisingly, there was a complete absence of signal when the
P2 fraction from diabetic rats was probed with the anti-
Gald3P-lysine antibody (Fig. 2D).
In order to assess comparatively the level of early glycation
products generated among endothelial plasma membrane
proteins by each of the three sugars under study, a semi-
Fig. 2. Representative silver-stained electrophoretic pattern of the endothelial
plasma membrane fractions purified from a normal (N) and a diabetic (D) rat
(A). Western blotting of the same samples with anti-glucitollysine (B), anti-
G6P-lysine (C) and anti-Gald3P-lysine antibodies (D).
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intensity of the western blotting signal recorded for each of the
corresponding antibodies with that of a series of standards
made from BSA carrying various amounts of sugar-lysyl
residues (Fig. 3, insets). We found a linear relationship between
the intensity of the immunochemical signal and the amount of
sugar in the domain encompassing the signal revealed for the
P2 proteins (Fig. 3A and B). By interpolation, we have
calculated that at 2 months of diabetes the rat lung endothelial
plasma membrane proteins carry simultaneously, on average,
1900 pmol of glucose and only 6.5 pmol of G6P per mg of
protein (Fig. 3C). As previously mentioned, virtually no
products of early glycation by Gald3P were detected among
the endothelial plasmalemmal proteins.Fig. 3. Semi-quantitative evaluation of the extent of protein glycation in the lung end
endothelial plasma membrane were adsorbed as dots on a nitrocellulose membrane a
glucose or glucose-6-phosphate). The membranes were incubated with anti-glucitolly
The intensity of the signal was measured by densitometry for each spot, used to const
the level of global protein glycation (C). Filled circles: the optical density (arbitrary u
proteins.In order to identify which are the lung endothelial plasma
membrane proteins forming early glycation products with
glucose and G6P, the P2 fraction was resolved by 2D
electrophoresis and probed with the corresponding antibodies.
The vast majority of the glycated proteins of this fraction are
distributed in the acidic part of the pI spectrum [20], so the
isoelectric focusing was performed, for a greater resolution,
in the narrower pH range of 4–7. Gel staining with either
silver nitrate or Sypro Ruby Red (Fig. 4A) revealed, in this
domain, more than five hundred individual spots forming a
reproducible 2D electrophoretic pattern of rat lung endothelial
plasma membrane proteins. This spectrum of spots was
present in all samples, independently purified from various
individual animals (n =6), and the relative position of the
spots was unchanged when the endothelial plasma membrane
fraction from normal rats was compared to that from diabetic
rats, or when the two were co-migrated in the same gel (not
shown).
The glycated proteins revealed by western blotting with
either anti-glucitollysine or anti-G6P-lysine antibodies repre-
sent only a fraction of the global spectrum of lung endothelial
plasmalemma proteins. Less than one hundred individual spots
or spot clusters were found to be positive for glucitollysine
(Fig. 4B) and only about fifty responded to the anti-G6P-lysine
antibody (Fig. 4C). Except the spots labeled 7a–c in Fig. 4C,
all polypeptides glycated by G6P contain glucose adducts too.
In spite of the higher sensitivity of the anti-G6P-lysine
antibody (Fig. 1), the intensity of the immunochemical signal
was significantly higher for glucitollysine, indicating to us that
glucose was the major intracellular glycating reagent.
The 2D electrophoretic pattern of endothelial plasma
membrane proteins from normal and diabetic rats were
consistently identical. No variations in the position of theothelial plasma membrane preparations from diabetic rats. Total proteins of lung
long a series of standards (glycated BSA containing various amounts of bound
sine (A) or anti-glucitol-6-phosphate lysine (B) and developed by ECL (insets).
ruct a standard curve for each hapten (A) and (B), and calculate by interpolation
nits) of the standards; open squares: the photometric readings for the membrane
Fig. 4. The spectrum of rat lung endothelial plasma membrane proteins comprised between pI 4.0 and 7.0. In gel staining with Sypro Ruby Red (A). Identification of
the glycated endothelial plasma membrane proteins by immunoblotting with anti-glycitol-lysine (B) and anti-glucitol-6-phosphate-lysine antibodies (C).
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proteins were ever recorded, and the images of the two could
be perfectly overlapped. This, in conjunction with the relative
simplicity of the electrophoretic pattern, allowed us to select
and excise the spots corresponding to 29 major endothelial
proteins found to be glycated in diabetes. We had to ignore
several other spots and spot clusters that, in spite of exhibiting
a strong signal for glucitollysine (Fig. 4B, upper left quadrant),
were present in amounts too small for their identification in the
Sypro Ruby Red stained gels. Mass spectrometry analysis of
the selected polypeptides (Fig. 4A, encircled spots) has
produced a list of rat lung endothelial plasma membrane
proteins susceptible to glycation in a hyperglycemic condition
(Table 1). Three of these – dipeptidyl peptidase IV, integrin
alpha 3 and chloride intracellular channel 5 – were integral
membrane proteins. The majority of the glycated proteins were
found to be cytoskeletal, belonging to the cell cortex, and
known or putative peripheral plasma membrane proteins. Only
three polypeptides could be bona fide considered as contami-nants, either from the circulation (albumin) or extracellular
matrix origin (laminin and collagen type VI).
4. Discussion
The ability of reducing sugars to bind covalently and non-
enzymatically to proteins depends on their concentration and
on the proportion at which these sugars are present in an
acyclic form [6]. Studies performed in vitro have shown that
the formation of Schiff bases between proteins and G6P
proceeds about ten times faster than for glucose, and that
Gald3P can glycate in the same time interval over 200 times
more aminoacid residues as the equimolar amounts of glucose
[5,21]. Consequently, glucose is considered as a weak
glycating sugar although, in the hyperglycemic condition of
diabetes, glucose is the glycation agent for plasma and
extracellular matrix proteins.
Glucose transport across the lung microvascular endotheli-
um plasma membrane is facilitated by the insulin-insensitive,
Table 1
List of the glycated proteins on the rat lung endothelial plasma membrane
Spot no. MS-identified proteins Accession number No. of peptides MW (Da) calculated pI calculated
1 Laminin gamma 1 chain precursor XP341134 3 172481 5.12
2 Procollagen type VI alpha 1 NP034063 12 109562 5.2
3a Procollagen type VI alpha 2 XP342116 3 122067 6.00
3b 3
4a Dipeptidyl-peptidase IV membrane-bound form P14740 7 89090 5.57
4b 9
4c 7
4d 7
5a Similar to Integrin alpha 3 XP340885 8 120843 6.43
5b 7
5c 6
5d 10
6a Gelsolin NM001004080 2 86067 5.75
6b 8
7a Ezrin AAR91694 12 69390 5.83
7b 8
7c 13
8a Heat shock cognate protein 70 NP077327 6 70871 5.37
8b 12
9 Annexin VI P48037 20 75754 5.39
10a Albumin P02770 1 70670 6.09
10b 1
11a Moesin/Radixin AAB61666/AAR91693 10 69405 5.83
11b 3
11c 3
11d 38
11e 10
11f 15
11g 12
11h 12
11i 17
11j 16
12 Chaperonin containing TCP-1 (5() AAH79441 6 59955 5.81
13 Tubulin alpha 1 AAH62238 8 50135 4.94
14 Vimentin P31000 14 53601 5.06
15a Similar to Septin 8 protein XP220423 4 53003 5.82
15b 2
16 ARP 3 homolog XM341113 8 55287 8.85
17 Tubulin, beta CAE84031 9 50096 4.78
18 Actin, beta P60711 10 41736 5.29
19a TPA: type I keratin KA19 DAA04480 13 44635 5.21
19b 8
20 Septin 2 NP476489 3 41592 6.15
21a Eukaryotic translation initiation factor 2,
Subunit 1 (alpha)
NP062229 3 36108 5.02
21b 4
22a Protein phosphatase 1 subunits h/ y/ g NP037197/1703464D/I76573 4 37248 5.84
22b 13
23 Annexin I P07150 14 39147 6.97
24a Annexin II NP063970 10 38939 7.55
24b 12
25 Annexin V 2RAN 22 35458 4.97
26 Annexin IV NP077069 4 35848 5.31
27 Annexin III LURT3 4 36363 5.96
28a Chloride intracellular channel 5 Q9EPT8 11 28298 5.64
28b 4
29a Similar to Polymerase I transcript release factor XP220982 4 43908 5.43
29b 2
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this transporter is not down regulated in streptozotocin-induced
diabetic rats (our unpublished results), the glucose concentra-
tion is expected to be significantly higher than normal in the
cytosol of the pulmonary endothelium of hyperglycemicanimals. No direct measurement of the sugar at this location
was ever made, but the assertion above is eloquently supported
by the high level of endothelial protein glycation by glucose in
diabetic rats (Fig. 2B). It is plausible to infer that in diabetes,
the increased availability of the substrate (glucose) accelerates
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ates such as G6P and Gald3P. It was therefore of a particular
interest to assess the involvement of all these sugars in the
glycation of intracellular proteins.
Despite the evidence that G6P and Gald3P are capable of
glycating proteins to a far greater extent than glucose in vitro,
our results point to glucose as the most important intracellular
glycating sugar. In the diabetic animals, more endothelial
proteins were glycated, and in far more extent, by glucose than
by G6P; virtually no protein modification by Gald3P was
recorded. A possible explanation for the discrepancy in levels
of glycation by the three sugars might reside in their
intracellular concentration. Our results point to a moderate
increase in G6P leading to the glycation of endothelial proteins
by this hexosephosphate (Fig. 2C), although at a level
approximately 300 times lower than that made by glucose
(Fig. 3C). The similarity of the electrophoretic patterns of
proteins carrying glucitollysine and G6P-lysine (Fig. 2B and C
and Fig. 4B and C) indicates that the two sugars compete for
the same polypeptides.
The surprising lack of detection, in the diabetic rats, of lung
endothelial plasma membrane proteins glycated by Gald3P
cannot be explained by a lack of reactivity of these proteins
with that particular phosphotriose. When endothelial plasma
membrane fractions isolated from normoglycemic animals
were incubated in vitro, in non reducing conditions, with
Gald3P a substantial increase in the level of glycation by
Gald3P was recorded, well correlated with the time of
incubation (not shown). Also, the ability to detect early
glycation products of Gald3P in vitro makes less plausible
the hypothesis that Gald3P-protein adducts progress so rapidly
towards AGEs [22] that they do not accumulate above the
detection limit of the method we used. In our view, the only
plausible explanation for the lack of detectable early Gald3P
glycated products in diabetic rats is the fact that, in spite of a
rise in intracellular level of glucose and G6P, the concentration
of Gald3P in the endothelial cells remains low. The competition
between these sugars might well account for the disappearance
of the two faint Gald3P positive bands recorded among the
endothelial membrane proteins of normoglycemic rats (Fig.
2D). To our knowledge, very few systematic measurements of
the phosphorylated intermediates of the glycolysis have been
made in nucleated cells, and none concerns endothelial cells. In
rat erythrocytes, the concentration of Gald3P is hundred of
times smaller than that of glucose [23]. Interestingly, the red
blood cells of diabetic patients contain double the amount of
hexosephosphates (G6P, fructose-6-phosphate and fructose-
1,6–bis-phosphate) found in the erythrocytes of normoglyce-
mic subject, but the level of the triosephosphates remains
unaltered [24]. Therefore, in spite of its well-documented, high
glycation potency in vitro, Gald3P does not appear to
participate significantly to the in vivo formation of early
glycation products with intracellular proteins.
We have previously shown that the majority of the
endothelial plasma membrane proteins targeted by glycation
are peripheral, plasmalemma-associated polypeptides [20].
Seventeen of the 29 proteins identified in this study as beingglycated belong indeed to this category. Six forms of annexins
(I to VI) each defined by several unique peptides were found
among the glycated polypeptides. Annexins are known to be
involved in a large variety of cell structure and physiology
aspects (reviewed in [25]). They seem to act as organizers/
stabilizers of the plasma membrane lipid microdomains or rafts
(annexins II and VI), as a link between the membrane and the
cortical cytoskeleton (annexin II); they also appear to be
involved in exo- and endocytosis (annexins I, II, V and VI) by
modulating vesicle docking and fusion, and presumably, able
to form transmembrane ion channels [26]. Directly concerning
the vascular endothelial functions is the anti-inflammatory
contribution of annexin I as a downregulator of the leukocyte
extravasation [27], as well as the status of a pro-fibrinolytic,
simultaneous receptor for plasminogen and tissue plasminogen
activator for annexin II [28]. Finding that these proteins are all
modified by glucose and G6P in hyperglycaemic conditions
opens to future investigations the question whether there is any
relationship between the glycation of annexins and diabetes-
associated endothelial dysfunction.
Elements of the plasma membrane-associated cytoskeleton
also represent an important target for nonenzymatic glycosyl-
ation. The proteins of the microfilaments (actin h, and actin
related protein 3) and their associated proteins (gelsolin and
septins 2 and 8) and well as those of the microtubules (tubulin
a and h) and intermediate filaments (vimentin and cytokeratin
K19) were found to be all glycated by glucose and G6P. Ezrin,
moesin and radixin are members of a family of proteins
involved in the functional association between the cell surface
and the cytoskeleton [29]. The large polymorphism of these
three proteins on the isoelectric focussing scale (Fig. 4) is not
surprising; up to 12 consensus sites for serine/threonine
phosphorylation are present in the sequence of moesin. Finding
that in diabetes many proteins of the endothelial cell cortex are
targeted by glycation allows us to hypothesize that this process
might be at the origin of the documented hyperglycemia-
associated alterations of the plasma membrane fluidity [30,31].
A group of five other glycated polypeptides – heat shock
cognate protein 70 (Hsc70), T-complex-containing protein 1
(TCP-1), eukaryotic translation initiation factor 2, protein
phosphatase 1 and polymerase I transcript release factor
(PTRF) – could be seen as elements of the cell internal
compartments contaminating the plasma membrane prepara-
tion. However, recurrent evidence suggests that some of them
are physically and functionally associated with the plasma
membrane too. Although localized in the cytosol and nucleus
(under stress), Hsc70 was detected at the plasma membrane and
putative roles in the immune response and signal transduction
have been attributed to his protein [32]; the plasma membrane
lipid rafts of adipocytes and HeLa cells concentrate most of the
PTRF, otherwise, a nuclear factor required for the termination
of the ribosomal RNA synthesis [33]. TCP-1 is a chaperonin
involved in the correct folding of actin and tubulin [34] and its
association with the cortical cytoskeleton appears therefore
natural.
Only three integral plasmalemmal proteins were recognized
among the endothelial glycated polypeptides (Table 1). The
S. Nguyen et al. / Biochimica et Biophysica Acta 1762 (2006) 94–102 101first is a cell surface enzyme—dipeptidyl peptidase IV. Its
activity was showed to decrease by 25% in the heart
vasculature of the STZ-induced diabetic rats [35]. In the
perspective of our results this loss of function might be the
consequence of this protein glycation. Although several other
integrins have been detected by a comprehensive proteomic
study at the luminal front of the rat lung endothelial plasma
membrane ([36], and our unpublished results), only the integrin
alpha 3 was consistently found to be glycated. The third
glycated integral membrane protein was identified as the
chloride intracellular channel 5 or CLIC5, which is a member
of a recently described family of proteins believed to be
involved in the control of the cellular water and electrolyte
balance. Although initially reported as residents of intracellular
compartments (hence the name), the members of the CLIC
family and particularly CLIC-5 have been recently localized by
biochemical fractionation and immunofluorescence at the
apical plasma membrane of polarized epithelia [37], in close
association with the cortical actin cytoskeleton [38].
An important question related to glycation is how many
sugar molecules are bound by each targeted protein in the real
conditions of diabetes. It is intriguing that the 2D electropho-
retic patterns of the glycated (from diabetic), and nonglycated
(from normoglycemic rats) endothelial plasmalemma proteins
are virtually identical and that they overlap perfectly. Glyca-
tion was expected to produce a shift in the electric charge of
the protein, particularly evidenced by isoelectric focussing in a
narrow pI domain. We did not observe any alteration of this
sort for any of the spots corresponding to glycated proteins. To
us, the only plausible explanation is that in each protein
targeted by glycation the number of aminoacid residues
affected is too small to change the electric balance of the
macromolecule. This is in accord with the few data in the
literature concerning the extent of glycation of intracellular
proteins in diabetes. Only 1% of the total (-amino groups of
the hemoglobin were found to be glycosylated in the
erythrocytes of the diabetic patients [39], while in the skeletal
muscle myofibrils of the diabetic rats this figure is approxi-
mately 0.05% [40]. In contrast, in long–lived proteins of
extracellular matrix like the collagen, the extent of glycation is
significantly higher: 2.5% of the total lysyl residues [41].
Several studies performed in vitro have emphasized that on
proteins such as albumin, hemoglobin, LDL and RNase,
sugars condense only with a few, selected aminoacid residues
[9,41–44]. These studies have also shown that, in spite of a
very limited number of available sites for glycation, the
reaction can have a pronounced effect on the protein ligand
binding capacity, recognition by its receptor or enzymatic
activity.
What is the impact of glycation, at levels existing in vivo,
on the functions of endothelial cell proteins identified
throughout this study is a question deserving further attention.
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